Dr. Raabe’s research focuses on translational neuro-oncology, with the overall goal being to develop new therapeutics for poor prognosis brain tumors. Dr. Raabe’s expertise is in stem cell biology, developmental biology and pre-clinical therapeutics. He has generated one of a handful of human diffuse intrinsic pontine glioma cell lines that form xenografts with high fidelity to the primary tumor and retain the H3F3A K27M mutation. He has expertise in targeting stem cell factors in aggressive brain tumors in vivo and in vitro. Dr. Raabe has developed normal human and mouse neural stem cells for use as genetically accurate gain-of-function models for high-risk brain tumors.
Dr. Raabe currently has a research group composed of research assistants, graduate students, and post-doctoral fellows. He continues to work closely with Dr. Charles Eberhart, who is a neuro-pathologist and core collaborator.
Lab Website: Eberhart, Rodriguez and Raabe Lab
Learn more about clinical trials at Johns Hopkins Medicine.
View all on PubMed
Mao, XG, Hutt-Cabezas, M, Orr, BA, Weingart, M, Taylor I, Rajan K, Odia Y, Kahlert U, Maciaczyk J, Nikkhah G, Eberhart CG*, Raabe EH*. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumor formation by enacting a pro-invasive genetic program. Oncotarget. 2013 Jul;4(7):1050-64. PMCID 3759665 * Co-corresponding author.
Kaur H, Ali SZ, Huey L, Hutt-Cabezas M, Taylor I, Mao XG, Weingart M, Chu Q, Rodriguez FJ, Eberhart CG, Raabe EH. The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett. 2016 Jul 10; 377(1):55-64. doi: 10.1016/j.canlet.2016.04.020. Epub 2016 Apr 18. PMID: 27102002
Hanaford AR, Archer TC, Price A, Kahlert UD, Maciaczyk J, Nikkhah G, Kim JW, Ehrenberger T, Clemons PA, Dancik V, Seashore-Ludlow B, Viswanathan V, Stewart ML, Rees M, Shamji AF, Schreiber SL, Fraenkel E, Pomeroy SL, Mesirov JP, Tamayo P, Eberhart CG*, Raabe EH*. DiSCoVERing innovative therapies for rare tumors: combining genetically accurate disease models with in silico analysis to identify novel therapeutic targets. Clin Cancer Res. 2016 Mar 24. PMID: 27012813. * Co-corresponding author.
Weingart MF, Roth J, Hutt-Cabezas M , Busse T , Kaur H, Price A, Maynard R, Rubens J, Taylor I , Mao XG, Xu J, Kuwahara Y, Allen SJ , Erdreich-Epstein A, Weissman BE , Orr BA , Eberhart CG, Biegel J, Raabe EH. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget, 2015 Feb 20;6(5):3165-77. PMCID: PMC4413645
Raabe, E.H., Lim, K.S., Kim, JM., Meeker, A., Mao, XG., Nikkhah, G., Macizczyk, J., Kahlert, U., Jain, D., Bar, E., Cohen, KJ, Eberhart CG. "BRAF Activation Induces Transformation and then Senescence in Human Neural Stem Cells: A Pilocytic Astrocytoma Model." Clinical Cancer Research, (2011) Jun 1;17(11):3590-9. PMCID: PMC4086658